Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

• the present invention relates to a composition for pharmaceutical tablets containing a polyvinyl alcohol-based resin and crystalline cellulose, a pharmaceutical tablet using the same, and a method for producing a pharmaceutical tablet.
• Tablets which are one of them, are generally manufactured by tableting.
• granules obtained by granulating a mixed powder obtained by mixing various additive components with an active ingredient (medicinal ingredient) as a medicine are filled in a die, or the mixed powder is directly pressed. It is filled into a die, pressed with a pestle and formed into the desired size and shape to form a pharmaceutical tablet. Molded tablets may also be coated, if desired.
• sustained-release tablets that control the release of medicinal ingredients over a long period of time can reduce side effects by improving compliance with a decrease in the number of doses and by reducing the fluctuation range of blood concentrations. are being actively researched and developed.
• excipients for solid formulations excipients (those that are added in an appropriate amount for handling and do not have physiological activity), binders (those that are added to bind the raw material powder particles together, control the mechanical strength of the tablet), disintegrants (added to facilitate the release of active ingredients by disintegrating the tablet by absorbing water in the body and swelling), lubricants (powder added to improve fluidity and facilitate compression molding).
• Polyvinyl alcohol (PVA) resin which is water-soluble and biodegradable, has excellent adhesive strength with various components, so it is used as an additive for pharmaceutical tablets (specifically, binders, tablet film coating agents, etc.). is used as Among additives, binders and disintegrants are known to affect the strength of tablets and the elution rate of active ingredients, and the use of polyvinyl alcohol resins in controlled release tablets has been investigated.
• Patent Document 1 adhesiveness is improved by using PVA fine particles having a gauche structure at a predetermined ratio or more from the particle surface toward the inside as a pharmaceutical binder.
• a sustained-release tablet imparting sustained-release properties has been proposed.
• PVA fine particles (pulverized product: 50% particle size 96 ⁇ m) having a saponification degree of 88% and an average polymerization degree of 2400 are added to a wet granulated mixture of a medicinal ingredient and crystalline cellulose, and crystalline cellulose and Aerosil are added.
• magnesium stearate and compression-molded tablets had a sustained release compared to PVA microparticles (pulverized product: 50% particle size 100 ⁇ m) with a low proportion of gauche structure (Fig. 5).
• metformin hydrochloride is used as a medicinal ingredient.
• Patent Document 2 Japanese National Publication of International Patent Application No. 2018-530537 (Patent Document 2), by pressing a combination (dry co-mixture) of PVA having an average particle size of less than 100 ⁇ m and microcrystalline cellulose as a matrix, tablets with high hardness are obtained. obtained is described.
• the tablet obtained here is a sustained-release tablet capable of releasing the active ingredient over a long period of time without depending on the composition of the release medium.
• Patent Document 2 as PVA, grades 26-88 (4% aqueous solution viscosity 26 mPa s, saponification degree 88%), 40-88 (4% aqueous solution A combination of pulverized PVA particles having a viscosity of 40 mPa s and a degree of saponification of 88% and having an average particle size (Dv50) of 85 to 88 ⁇ m and microcrystalline cellulose having an average particle size (Dv50) of 100 to 140 ⁇ m. is compressed at 10 kN, 20 kN, and 30 kN, and the dissolution rate is measured by changing the medium.
• Patent Document 2 it is shown that the tablet hardness depends on the compression pressure (Fig. 1), and when the particle size is adjusted within the above range, a tablet hardness of 200 N or more can be achieved at a compression pressure of 20 kN or more. is disclosed.
• the release rate after 10 hours tends to decrease as it increases, for example, in FIG. 2a (compression pressure 10 kN), FIG. 2b (compression pressure 20 kN), and FIG. , Tables 2a, 2b, and 2c of the phosphate buffer results showed that the average values after 10 hours were 89%, 88%, and 85%, and the maximum values were 91%, 90%, and 87%. there). Furthermore, even after 12 hours, 100% cannot be reached, and it is considered that the release is difficult.
• the present invention has been made in view of such circumstances, and the purpose thereof is to provide a high hardness to the extent that it is difficult to chew, suppress dissolution for several hours after administration, and ten minutes after administration.
• An object of the present invention is to provide a composition for sustained-release tablets that can release 90% or more of the medicinal ingredients after a period of time, a sustained-release tablet using the same, and a method for producing the same.
• the pharmaceutical tablet composition of the present invention contains a polyvinyl alcohol-based resin and crystalline cellulose, has a viscosity of 4% by mass aqueous solution of polyvinyl alcohol of more than 44 mPa ⁇ s, and an average particle size of 100 ⁇ m or less.
• the average particle size of the crystalline cellulose is preferably 250 ⁇ m or less, and is preferably 0.5 times or less or 2 times or more the average particle size of the polyvinyl alcohol resin.
• the blending ratio of the polyvinyl alcohol-based resin and the crystalline cellulose is preferably 100/200 to 100/1 by weight.
• the weight ratio of the polyvinyl alcohol-based resin to the crystalline cellulose is more than 2/1 and 50/1 or less.
• the polyvinyl alcohol-based resin and the crystalline cellulose are preferably blended so that the tap density is 0.50 to 0.68 g/mL.
• polyvinyl alcohol having a 4% by mass aqueous solution viscosity of greater than 44 mPa s and an average particle size of 100 ⁇ m or less; and crystalline cellulose having an average particle size of 250 ⁇ m or less.
• a pharmaceutical tablet composition for The average particle size of the crystalline cellulose is 0.5 times or less or 2 times or more the average particle size of the polyvinyl alcohol-based resin, and the blending ratio of the polyvinyl alcohol-based resin and the crystalline cellulose (polyvinyl alcohol-based resin/crystalline cellulose) is greater than 2/1 to 50/1 by weight.
• the degree of saponification of the polyvinyl alcohol-based resin is preferably 70 mol% or more and 100 mol% or less.
• the present invention also includes pharmaceutical tablets containing the composition for pharmaceutical tablets of the present invention as described above and a medicinal ingredient belonging to class I or III of the BCS classification.
• Said pharmaceutical tablet is preferably a sustained release tablet.
• Another aspect of the present invention is a method for manufacturing a pharmaceutical tablet.
• a mixture containing a medicinal ingredient; crystalline cellulose; and a polyvinyl alcohol-based resin having an average particle size of 100 ⁇ m or less and a 4 mass% aqueous solution viscosity of more than 44 mPa s is tableted. Including process.
• the medicinal ingredient is preferably a granule granulated using a binder.
• the average degree of saponification refers to the degree of saponification measured by a method conforming to JIS K 6726 (1994).
• the "4% by mass aqueous solution viscosity at 20°C" referred to in the present invention can be measured by the following method. That is, 500 g of water and 25 g of PVA-based resin are mixed, stirred at 60 to 100° C. for 60 minutes, and completely dissolved, and then water is added to prepare a 4 mass % aqueous solution. This 4% aqueous solution was held in a constant temperature water bath at 20°C for 30 minutes or more, and after confirming that the aqueous solution temperature reached 20°C, the 4% by mass was obtained by the falling ball viscometer method according to JIS K6726. Measure the viscosity of the aqueous solution.
• the average degree of polymerization referred to in this specification is the average degree of polymerization (number average degree of polymerization) measured by a method conforming to JIS K 6726 (1994).
• the sum of the number average degrees of polymerization obtained by multiplying the respective content ratios is usually obtained.
• the average particle size referred to in this specification is the average value of particle sizes measured by the laser diffraction method.
• composition for pharmaceutical tablets of the present invention it is possible to manufacture tablets with such a high hardness that it is difficult to chew them. Even if it is a medicinal ingredient, it is excellent in sustained release.
• composition for pharmaceutical tablets of the present invention comprises a matrix base polyvinyl alcohol resin (A) having a particle size within a predetermined range and a 4% aqueous solution viscosity, and crystalline cellulose (B).
• A matrix base polyvinyl alcohol resin
• B crystalline cellulose
• the polyvinyl alcohol (PVA)-based resin used in the composition for solid preparations according to the present invention is obtained by saponifying a polyvinyl ester-based resin obtained by polymerizing a vinyl ester-based monomer.
• the resulting resin is mainly composed of vinyl alcohol structural units, and has vinyl alcohol structural units corresponding to the degree of saponification and vinyl ester structural units of unsaponified portions. It is not limited to unmodified PVA resins consisting of vinyl alcohol units and vinyl ester units, but saponifies polyvinyl ester resins obtained by polymerizing vinyl ester monomers and monomers having copolymerizability (copolymerizable monomers).
• the degree of modification (content of structural units other than vinyl alcohol units and vinyl ester structural units) is 20 mol % or less, preferably 1 mol % or more and 10 mol % or less, more preferably 1 It is mol % or more and 5 mol % or less.
• vinyl ester monomers examples include vinyl formate, vinyl acetate, vinyl propionate, vinyl valerate, vinyl butyrate, vinyl isobutyrate, vinyl pivalate, vinyl caprate, vinyl laurate, vinyl stearate, vinyl benzoate, and Versatic. Examples thereof include vinyl acetate, and vinyl acetate is practically preferable.
• Examples of the copolymerizable monomer include olefins such as ethylene, propylene, isobutylene, ⁇ -octene, ⁇ -dodecene, ⁇ -octadecene, 3-buten-1-ol, 4-penten-1-ol, 5- Hydroxy group-containing ⁇ -olefins such as hexen-1-ol and 3,4-dihydroxy-1-butene, and derivatives such as acylated products thereof; acrylic acid, methacrylic acid, crotonic acid, maleic acid, maleic anhydride, itaconic acid , unsaturated acids such as undecylenic acid, salts thereof, monoesters, or dialkyl esters thereof; nitriles such as acrylonitrile and methacrylonitrile; amides such as diacetone acrylamide, acrylamide, and methacrylamide; Olefinsulfonic acids such as allylsulfonic acid or salts thereof; Al
• modified PVA-based resin obtained by copolymerization with unsaturated acids, salts thereof, monoesters, or dialkyl esters for example, polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer is preferable.
• a modified PVA-based resin having a primary hydroxyl group in the side chain is also preferably used.
• Such modified PVA-based resins include, for example, copolymerizable monomers such as 3,4-diacetoxy-1-butene, vinylethylene carbonate, and glycerin monoallyl ether; It can be obtained by using a copolymerizable monomer having a hydroxymethyl group in a side chain such as hydroxymethylvinylidene diacetate such as propionyloxy-2-methylenepropane, 1,3-dibutyronyloxy-2-methylenepropane.
• a method of saponifying a copolymer of a vinyl ester monomer and 3,4-diacetoxy-1-butene (b) a method of saponifying a copolymer of a vinyl ester monomer and vinyl ethylene carbonate and (c) a method of saponifying and deketalizing a copolymer of a vinyl ester monomer and 2,2-dialkyl-4-vinyl-1,3-dioxolane; (d) a vinyl ester monomer
• a modified PVA-based resin having a 1,2-diol bond in the side chain can be obtained by a method of saponifying a copolymer of and glycerin monoallyl ether.
• the modified PVA-based resin may be a post-modified PVA-based resin obtained by post-modifying unmodified PVA.
• Post-modification methods include acetoacetic esterification, acetalization, urethanization, etherification, phosphate esterification, oxyalkylenation, and the like.
• the method of polymerizing the vinyl ester monomer (and optionally the copolymerizable monomer) can be carried out by a conventionally known method (bulk polymerization, solution polymerization, suspension polymerization, dispersion polymerization, emulsion polymerization, etc.).
• a conventionally known method bulk polymerization, solution polymerization, suspension polymerization, dispersion polymerization, emulsion polymerization, etc.
• known ones can be employed.
• An alcohol is usually used, preferably a lower alcohol having 1 to 3 carbon atoms.
• Saponification of the resulting vinyl ester polymer can also be carried out by a conventionally known method.
• the polymer can be dissolved in an alcohol or water/alcohol solvent using an alkali catalyst or an acid catalyst.
• an alkali catalyst for example, hydroxides and alcoholates of alkali metals such as potassium hydroxide, sodium hydroxide, sodium methylate, sodium ethylate, potassium methylate and lithium methylate can be used.
• Saponification is usually preferably carried out by transesterification using an alkali catalyst in the presence of an anhydrous alcoholic solvent, from the viewpoint of the reaction rate and the reduction of impurities such as fatty acid salts.
• the reaction temperature for the saponification reaction is usually 20-60°C. If the reaction temperature is too low, the reaction rate tends to decrease and the reaction efficiency tends to decrease.
• saponification can be performed at a higher temperature, for example, 80 to 150 ° C., and a small amount of saponification catalyst is used. It is also possible to obtain a high degree of saponification in a short period of time.
• the cleaning liquid include alcohols such as methanol, ethanol, isopropyl alcohol, and butanol, and methanol is preferable from the viewpoint of cleaning efficiency and drying efficiency.
• the temperature during washing is usually 10 to 80°C, preferably 20 to 70°C. Washing times are typically from 5 minutes to 12 hours.
• the washed PVA-based resin is washed with a lower alcohol such as methanol and then dried with hot air or the like in a continuous or batch manner to obtain PVA-based resin powder.
• the drying temperature is generally 50 to 150°C, preferably 60 to 130°C, particularly preferably 70 to 110°C.
• the drying time is usually 1 to 48 hours, preferably 2 to 36 hours.
• the content of the solvent contained in the PVA-based resin after drying is usually 0% by weight or more and 10% by weight or less, more preferably 0.1% by weight or more and 5% by weight or less, and still more preferably 0.1% by weight or more and 5% by weight or less. It is 1% by weight or more and 1% by weight or less.
• the average degree of saponification of the PVA-based resin used in the present invention is 78 to 96 mol% as defined in the Japanese Pharmaceutical Excipients Standards (JPE) for polyvinyl alcohol (partially saponified product), preferably the European Pharmacopoeia. (EP), 85-89 mol %, satisfying all of the United States Pharmacopeia (USP).
• JPE Japanese Pharmaceutical Excipients Standards
• EP European Pharmacopoeia.
• USP United States Pharmacopeia
• the number average degree of polymerization of the PVA-based resin is usually 2000 or more, preferably 2200 or more and 4000 or less, more preferably 2400 or more and 3500 or less, and particularly preferably 2450 or more and 3000. It is below. If the number-average degree of polymerization is too low, the formed gel density (network density) is considered to be insufficient, and initial drug release inhibition tends to be insufficient.
• the 4% by mass aqueous solution viscosity at 20°C of the PVA-based resin used as the matrix in the present invention is 44 mPa s or more, preferably 45 mPa s or more and 70 mPa s or less, more preferably 46.5 mPa s or more and 60 mPa s. ⁇ It is less than or equal to s. If the 4% by mass aqueous solution viscosity is too high, it means that the average degree of polymerization of the PVA-based resin is too high, and the compression moldability tends to deteriorate.
• the shape of the PVA-based resin is usually powder, granules, etc., preferably powder or granules.
• the average particle size of the PVA-based resin (particle size measured by laser diffraction method) is 100 ⁇ m or less, preferably 30 ⁇ m or more and less than 100 ⁇ m, more preferably 35 ⁇ m or more and 85 ⁇ m or less, still more preferably 40 ⁇ m or more and 75 ⁇ m or less, most preferably 40 ⁇ m. It is more than 60 micrometers or less. If the average particle size is too large, it is difficult to obtain a high bulk density, making it difficult to obtain tablets with high hardness. On the other hand, if the average particle size is too small, there is a tendency that the productivity in pulverizing the particles is lowered and the fluidity is lowered.
• the PVA-based resin powder having an average particle size within the above range may be obtained by synthesis, or may be a pulverized PVA-based resin obtained by synthesis.
• the tap density is usually 0.60 to 0.75 g/mL, preferably 0.61 to 0.68 g/mL.
• the content of the PVA-based resin in the pharmaceutical tablet is usually 5 wt% or more and 90 wt% or less, preferably 10 wt% or more and 80 wt% or less, and particularly preferably 20 wt% or more and 70 wt% or less. If the content is too low, it tends to be difficult to obtain sustained release properties of the tablet, and if it is too high, the hardness of the tablet tends to decrease.
• Crystalline cellulose is contained as an excipient. Since crystalline cellulose is excellent in compression moldability, the inclusion of such crystalline cellulose can increase the compression ratio and, in turn, increase tablet hardness to a hardness that makes it difficult to chew.
• the average particle size of the crystalline cellulose used in the present invention is not particularly limited, it is usually 250 ⁇ m or less. If the average particle size of the crystalline cellulose is too small, the fluidity of the powder tends to be low, and if the average particle size is too large, the compression moldability tends to be low.
• (Dc) of the crystalline cellulose and the average particle size (Dp) of the matrix PVA-based resin it is preferable that there is a difference between the two average particle sizes.
• (Dc/Dp) is preferably 1.5 or more, more preferably 2 or more and 5 or less, more preferably 4 or less.
• (Dc/Dp) is less than 0.7, more preferably 0.5 or less.
• the preferred average particle size of the crystalline cellulose used in the present invention is within the above range, and the tap density in combination with the matrix PVA-based resin (mixture state) is preferably 0.50 to 0.68 g/mL. , more preferably 0.52 to 0.65 g/mL, still more preferably 0.55 to 0.0.63 g/mL.
• the tap density of the combination (mixture state) of the matrix PVA-based resin and the crystalline cellulose tends to be lower than the tap density of the matrix PVA-based resin alone.
• the particle size distribution is broadened due to the difference in average particle size between the two, the porosity after compression tends to decrease, and as a result, it is possible to achieve high tablet hardness.
• the content of the crystalline cellulose is not particularly limited, it is preferable from the viewpoint of sustained release effect that the content of the PVA-based resin for the matrix and the content of the crystalline cellulose be equal to each other. .
• the content ratio (weight ratio) of PVA-based resin/crystalline cellulose is usually in the range of 100/200 or more and 100/1 or less, preferably more than 2/1, more preferably 3/1 or more, It is more preferably 5/1 or more, preferably 50/1 or less, more preferably 15/1 or less, and still more preferably 10/1 or less.
• the composition containing PVA-based resin and crystalline cellulose as a matrix base material is a hard tablet that is difficult to chew in the oral cavity despite the high content of PVA-based resin, and
• the release of the medicinal ingredient is suppressed (for example, 55% or less, preferably 50% or less 1 hour after administration, and the increase in dissolution rate after 1 hour to 3 hours is 35% or less, preferably 30% or less. ), and 90% or more of the active ingredient can be dissolved after 10 hours.
• the average particle size of the crystalline cellulose to be combined can be reduced to increase the packing density. is adjusted to be high, even if it is a medicinal ingredient that is easily water-soluble (for example, class I or class III in the BCS classification), the initial elution is suppressed by forming a dense gel with the PVA-based resin, High hardness of tablets can be achieved.
• the solid formulation composition of the present invention may contain various additives within a range that does not impair the effects of the present invention (20% by weight or less, preferably 10% by weight or less of the composition). can be done.
• Other additives include, for example, excipients, binders, disintegrants, pH adjusters, fluidizing agents, surfactants, coloring agents, sweeteners and coating agents.
• Binders are added during dry or wet granulation, direct compression, and wet manufacturing to provide binding between particles. Such binders are preferably used to control the disintegration of solid preparations (tablets).
• the binder is usually 0.1 to 10 parts by weight, preferably 0.2 to 5 parts by weight, more preferably 0.5 to 3 parts by weight, per 100 parts by weight of the composition, depending on the type of compound used. be.
• the polyvinyl alcohol-based resin that can be used as a binder may be an unmodified PVA-based resin, or a modified PVA-based resin using a copolymerizable monomer as described for the polyvinyl alcohol-based resin used in the matrix base material. It may be resin. When a polyvinyl alcohol resin is used as a binder, it is preferably dissolved in water to form an aqueous solution.
• the polyvinyl alcohol-based resin used as the binder is distinguished from the polyvinyl alcohol-based resin contained as the matrix base material in at least a 4% aqueous solution viscosity. That is, the viscosity of a 4% by mass aqueous solution of the polyvinyl alcohol resin used as the binder at 20° C. is preferably 2 mPa ⁇ s or more and 30 mPa ⁇ s or less, more preferably 2 mPa ⁇ s or more and 20 mPa ⁇ s or less, and particularly preferably A PVA-based resin having a polymerization degree of 2 mPa ⁇ s or more and 10 mPa ⁇ s or less and having a lower degree of polymerization than the matrix PV-based resin is usually used.
• the degree of saponification is preferably 70 mol % or more and 99 mol % or less, more preferably 80 mol % or more and 90 mol % or less, like the PVA-based resin for the matrix base material.
• the tablet When a polyvinyl alcohol resin as described above is used as a binder, the tablet contains two or more types of polyvinyl alcohol resins with different average degrees of polymerization. When two or more types of polyvinyl alcohol resins having different average degrees of polymerization are included, the average degree of polymerization of the polyvinyl alcohol resins contained in the entire composition for solid formulation is the average degree of polymerization of each polyvinyl alcohol resin. It will be the sum of the values multiplied by the percentage.
• a PVA-based resin for the matrix and a PVA-based resin for the binder when using two types of PVA-based resins, a PVA-based resin for the matrix and a PVA-based resin for the binder, the degree of saponification SDm and the degree of polymerization Pm of the PVA-based resin used as the matrix and the degree of polymerization Pm of the PVA-based resin used as the binder are
• Average degree of saponification SDm x M + SDb x B
• Average degree of polymerization Pm x M + Pb x B
• the content ratio (B) of the PVA-based resin for the binder is at most about 5% by weight of the entire PVA-based resin (usually 3% by weight or less, preferably 2.5% by weight or less), so the average degree of polymerization Even when the binder PVA-based resin is less than 800, the average degree of polymerization of the PVA-based resin contained in the tablet composition is 2000 or more.
• C-2 Other Binders
• binders in addition to PVA-based resins, dextrin, gum arabic, gelatin, hydroxypropyl starch, methyl cellulose, hydroxypropyl cellulose, hypromellose, pullulan, starch paste, and the like may be used. .
• Lubricants are contained to improve fluidity. is added to prevent sticking of tablets. Specifically, stearic acid, magnesium stearate, calcium stearate, talc, anhydrous silicic acid, and the like can be used.
• excipients include sugar alcohols (mannitol, erythritol, xylitol, sorbitol, maltitol, etc.), sugars (glucose, fructose, lactose, white sugar, trehalose, maltose, oligosaccharides, etc.), calcium phosphates, starches, Examples include sodium phosphates and gelatin, among which sugar alcohols, particularly mannitol, are preferably used.
• disintegrants carmellose calcium, carboxymethyl starch sodium, croscarmellose sodium, crospovidone, non-crystalline cellulose or derivatives thereof and starch or derivatives thereof, etc.
• pH adjusters citric acid and its salts, phosphoric acid and its salts, carbonic acid and its salts, tartaric acid and its salts, fumaric acid and its salts, acetic acid and its salts, amino acids and its salts, succinic acid and its salts and lactic acid and its salts, etc.
• agents light anhydrous silicic acid, hydrous silicon dioxide, titanium oxide, stearic acid, corn gel, heavy silicic anhydride, etc.
• surfactants phospholipids, glycerin fatty acid esters, polyoxyethylene fatty acid esters, sorbitan fatty acid esters, polyethylene Glycol fatty acid esters, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ethers, sucrose fatty acid esters,
• the sustained-release tablet of the present invention is a tablet obtained by adding an active ingredient to the pharmaceutical tablet composition of the present invention and tableting.
• the release rate and release time of the active ingredient from the tablet has sustained release properties.
• Medicinal ingredients that can be applied to the solid tablet of the present invention include antipyretic analgesic antiphlogistic drugs, tonic health drugs, psychotropic drugs, antidepressants, antianxiety drugs, sedative hypnotics, antispasmodics, drugs acting on the central nervous system, and cerebral metabolism.
• improving agent cerebral circulation improving agent, antiepileptic agent, sympathomimetic agent, gastrointestinal agent, antacid agent, antiulcer agent, antitussive expectorant agent, antiemetic agent, respiratory stimulant, bronchodilator, allergy agent, antihistamine agent, dentistry Oral drugs, cardiotonic agents, antiarrhythmic agents, diuretics, antihypertensive agents, vasoconstrictors, coronary vasodilators, peripheral vasodilators, anticoagulants, antihyperlipidemic agents, choleretic agents, antibiotics, Chemotherapeutic agents, antidiabetic agents, osteoporotic agents, antirheumatic agents, skeletal muscle relaxants, antispasmodics, hormone agents, alkaloid narcotics, sulfa agents, antigout agents, antineoplastic agents and the like.
• the tablet composition of the present invention has a high hardness and can impart sustained release properties, the active ingredient that requires sustained release (particularly, the active ingredient itself is readily water-soluble, so sustained release at the initial stage of administration is required.
• Active ingredients for oral administration such as those described in the literature), especially in combination with highly water-soluble active ingredients that not only reduce the effectiveness of sustained-release tablets when chewed, but also cause problems of side effects. Effective.
• the easily water-soluble medicinal ingredient is classified into, for example, the solubility shown in the 18th revision of the Japanese Pharmacopoeia, which is extremely soluble in water, easily soluble, and slightly soluble.
• Drugs, drugs classified as Classes I and III in the BCS classification, etc. BCS classification is a classification based on the solubility and membrane permeability of active ingredients. Class I has high solubility and high membrane permeability, and Class III has high solubility but low membrane permeability. Different from class I.
• water-soluble medicinal ingredients specifically medicinal ingredients that can be completely dissolved or highly soluble in an aqueous solvent of 250 mL or less in a pH range of 1.2 to 6.8 at 37 ⁇ 1 ° C.
• Metformin Hydrochloride Sodium Salicylate, Aminopyrine, Benzydamine Hydrochloride, Thiaramide Hydrochloride, Doxycycline Hydrochloride Hydrate, Moxalactam Sodium, Bacampicillin Hydrochloride, Levamisole Hydrochloride, dl-Methylephedrine Hydrochloride, Noscapine, Codeine Phosphate Hydrate dihydrocodeine phosphate, cloperastine hydrochloride, dl-isoprenaline hydrochloride, L-ethylcysteine hydrochloride, L-methylcysteine hydrochloride, tolperisone hydrochloride, eperisone hydrochloride, tizanidine hydrochloride,
• the content of the active ingredient (API) as described above is usually 0.5/100 or more and 1000/100 or less, preferably 20/100 or more and 500, in terms of matrix PVA-based resin/API (weight ratio). /100 or less, more preferably 30/100 or more and 300/100 or less.
• the method for producing the pharmaceutical tablet of the present invention includes the steps of mixing the composition for pharmaceutical tablets of the present invention and a medicinal ingredient, and tableting the mixture.
• the content ratio of crystalline cellulose and PVA-based resin, PVA-based resin/crystalline cellulose is 100/1 or more and 100/200 or less, preferably more than 2/1, more preferably 3/ It is preferably 1 or more, more preferably 5/1 or more, preferably 50/1 or less, more preferably 15/1 or less, further preferably 10/1 or less.
• the relationship (Dc/Dp) between the average particle size (Dc) of the crystalline cellulose and the average particle size (Dp) of the matrix PVA resin is 1.5/1 to 5/1, or 0.5 or less. Mixing in such a combination is preferred.
• the mixture of various components may be directly tableted, or the mixture may be granulated and then tableted.
• the granules are tableted, the granules containing the binder and the active ingredient are first produced, and the remaining granules (PVA-based resin for matrix and crystalline cellulose ) and tableting.
• the pharmaceutical tablet of the present invention is formed by tableting so that the active ingredient is homogeneously dispersed in the matrix PVA-based resin.
• the medicinal ingredient can be confined in a matrix gel formed of the matrix PVA-based resin. It becomes possible, and an effective sustained release effect can be obtained. Since a medicinal ingredient can be confined in a matrix gel (hydrogel) using hydrogen bonding, sustained release can be achieved even for medicinal ingredients classified as readily water-soluble.
• a conventional tablet manufacturing method can be applied as long as it is a method of tableting such that the medicinal ingredient is homogeneously dispersed in the matrix PVA-based resin.
• compression tableting methods such as a direct powder compression method (direct compression method), a semi-dry granule compression method, a granule compression method, etc.;
• the direct powder compression method is a method of directly mixing a drug and an additive and compression-molding the mixture without adding water.
• granules are granulated (slugging) by a dry method and then tableted. Better homogeneity than direct powder compaction.
• a semi-dry granule compression method or a semi-direct compression method is a method in which granules containing only additives without a drug are granulated by a wet method, a drug is added thereto, and the granules are tableted.
• the wet granule compression method is a method of tableting granules obtained by granulating a drug and additives by a wet method.
• the wet method is a method in which a wet kneaded product is poured into a certain direction or punched out, and then dried to remove solvents such as water.
• a mixture (granulation composition) in which other additives are added and mixed in addition to the binder PVA-based resin and the medicinal component may be granulated.
• a binder solution is added to the powder and granulated as it is, or a wet method in which a wet mass that has been kneaded is granulated; a dry method of granulating; and a spray granulation method of granulating by spray-drying a slurry of powder with a large amount of water.
• the solvent used in the binder solution is appropriately selected according to the type of compound used as the binder.
• water can be used as a solvent.
• Granulators include a dry granulator (a powder is subjected to a strong pressure to form a lump while it is in a dry state, and then pulverized into a powder having an appropriate particle size), a basket-type extrusion granulator, Stirring granulator (the raw material powder is mixed with a stirring blade for a few minutes, then the binder solution is added dropwise to perform stirring granulation), centrifugal tumbling granulator, fluid bed granulator (powder raw material is pneumatically It is fluidized and mixed, and the binder solution is sprayed from a nozzle in convection or countercurrent to this, the powder raw material is aggregated by the spray droplets, and further dried to promote particle growth), spray dryer (spray dry granulator) and the like can be used.
• a dry granulator a powder is subjected to a strong pressure to form a lump while it is in a dry state, and then pulverized into a powder having an appropriate particle
• a wet granulation method is, for example, a process in which each component is kneaded with a solvent and then granulated.
• this treatment include a crushing granulation method, an extrusion granulation method, a stirring granulation method, a tumbling granulation method, and the like.
• alcohols such as ethanol and isopropanol, and water are used as solvents.
• the granules are tablet-molded.
• the PVA-based resin for the matrix and the crystalline cellulose are preferably mixed with the granules at the time of tableting, and a lubricant is preferably added and mixed together in order to improve the compression moldability.
• any manufacturing method by compression molding of solid tablets using a rotary tableting machine, a single-shot tableting machine, or the like, which is commonly used in the pharmaceutical field, can be used.
• it is manufactured by a direct powder compression method in which various ingredients are uniformly mixed and then tableted, or a wet granule compression method or a dry granule compression method in which various ingredients are wet-granulated or dry-granulated and the resulting granules are tableted.
• the wet granule compression method is preferable from the viewpoint of improvement of fluidity and mixing uniformity.
• the compression pressure (tabletting pressure) in compression molding is preferably about 1 kN or more, more preferably about 5 kN or more, even more preferably about 10 kN or more, and may be 20 kN or more. Higher compression pressures tend to result in tablets with higher hardness. On the other hand, in order to avoid tablet cracking and the like, it is preferably about 60 kN or less, more preferably about 50 kN or less, and even more preferably about 40 kN or less.
• any shape such as an ellipsoid, cylinder, donut, or sphere can be adopted for the shape of the pharmaceutical tablet.
• the obtained tablet may be coated with a film, if necessary.
• the sustained-release tablet produced as described above generally has a hardness of 30 to 250 N and a hardness of 30 to 200 N, preferably 50 to 200 N, more preferably 70 to 200 N for a tablet with a diameter of 11 mm, although it depends on the form and size of the tablet. It can satisfy the required hardness as a sustained-release tablet (especially a sustained-release tablet for oral administration).
• the sustained-release tablet of the present invention was tested for dissolution test based on Dissolution Test 1 of USP41 "Metformin Hydrochloride extended-Release Tablets" using dissolution tester NTR-6400ACT (manufactured by Toyama Sangyo Co., Ltd.). Then, when a dissolution test was performed on 500 mg of the tablet manufactured by the above method in 1000 mL of phosphate buffer of pH 6.8 at 37°C, the dissolution rate after 10 hours from the start of measurement (the dissolution rate almost reached a plateau) was Assuming 100%, the release amount of the active ingredient after 1 hour and 3 hours can satisfy the following ranges.
• Dissolution rate A dissolution test for tablets containing water-soluble metformin hydrochloride as a medicinal ingredient was performed based on Dissolution Test 1 of USP41 "Metformin Hydrochloride extended-Release Tablets". Specifically, a 500 mg tablet was subjected to a dissolution test in 1000 mL of pH 6.8 phosphate buffer at 37 ° C., and after 1 hour and 3 hours using a dissolution tester NTR-6400ACT (manufactured by Toyama Sangyo Co., Ltd.) , and the dissolution rate (%) of the active ingredient after 10 hours was measured.
• the obtained mixture was tableted at a tableting pressure of 25 kN using a rotary tableting machine ("HT-EX12SS-U" manufactured by Hata Iron Works Co., Ltd.) to prepare pharmaceutical tablets (diameter 11 mm, weight 500 mg). .
• the obtained tablets were measured for tablet hardness and dissolution rate based on the evaluation methods described above. Table 1 shows the results.
• the dissolution rate after 3 hours and 10 hours is the dissolution rate (*1) at each time in the upper row, and the increase in dissolution rate (%) in the lower row.
• No. 1-6 are cases where the 4% aqueous solution viscosity is 45 mPa ⁇ s or more and the average particle size of the PVA-based resin is less than 100 ⁇ m. Compared to the dissolution rate after 1 hour, the increase in the dissolution rate after 3 hours could be suppressed to about 30%, but the dissolution rate after 10 hours was 90% or more, preferably 95% or more. In other words, it can be seen that sustained release and efficient elution of the medicinal ingredient could be achieved.
• No. 8-10 are the cases of using a matrix PVA-based resin with a low 4% aqueous solution viscosity, and the hardness of the obtained tablets tended to be low. Furthermore, No. When the viscosity of the 4% aqueous solution was too low as in No. 9, the initial dissolution rate was high and the sustained release was not achieved, probably because the network structure of the gel formed by the matrix PVA was insufficient. Recognize.
• No. 1-7 is a case where the average degree of polymerization of the matrix PVA resin is the same, but the average particle size (Dc) of the crystalline cellulose and the average particle size (Dp) of the matrix PVA differ from 1 (for example, Dc /Dp of 3 or more or 0.5 or less), the tablet hardness tended to increase. This is presumably because, in the compressed state (tablet state), one of the particles could enter the interparticle gaps of the other, and the void ratio of the tablet decreased.
• No. 4-7 has a Dc / Dp of about 0.8 to 1.2, which is close to 1, so it is difficult to form a densely packed state even in a compressed state (tablet state), resulting in a sufficient increase in tablet hardness. could not be achieved.
• the pharmaceutical tablet of the present invention can increase tablet hardness without impairing sustained release at the initial stage of administration and high dissolution of medicinal ingredients after 10 hours. Therefore, by using the composition for pharmaceutical tablets of the present invention, it is possible to provide effective sustained-release tablets even for readily soluble drugs that are classified into BCS classes I and III.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Diabetes (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Medicinal Preparation (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=85322795

Family Applications (1)

Country Status (5)

Cited By (1)

Families Citing this family (1)

Citations (3)

Family Cites Families (3)

• 2022
  • 2022-08-23 WO PCT/JP2022/031674 patent/WO2023027056A1/ja not_active Ceased
  • 2022-08-23 JP JP2023543922A patent/JPWO2023027056A1/ja active Pending
  • 2022-08-23 CN CN202280057344.9A patent/CN117836005A/zh active Pending
  • 2022-08-23 EP EP22861344.4A patent/EP4393512B1/en active Active
• 2024
  • 2024-02-09 US US18/437,576 patent/US20240173260A1/en active Pending

Patent Citations (3)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events